(TheNewswire)
Vancouver, British Columbia / TheNewswire / February 21, 2018 – BioMark Diagnostics Inc .
(“BioMark”) (CSE: BUX, FSE: 20B , OTC MKTS: BMKDF ) is pleased to provide an
update on its Health Canada submission progress following data analysis on its clinical trial activities.
Listed below are new accomplishments over the past 2 weeks:
-
1. BioMark’s regulatory team at St. Boniface Hospital Research Centre and the assigned
biostatistician have completed detailed data analysis and tabulation on clinical trials based in Canada and Bangladesh.
-
2. A comprehensive medical follow up report of the outliers in both in Canada and Bangladesh has been
reviewed by Dr. Andrew Maksymiuk, the Principal Investigator at CancerCare Manitoba along with our regulatory team members from
St. Boniface Hospital Research Centre. Initial assessment report of the outliers demonstrates BioMark SSAT1 technology can
provide physicians an economical diagnostic tool to effectively pre-screen patients for either more expensive CT screening or
more invasive biopsy procedure. (Outliers are subjects who were considered healthy but exhibited higher than expected Acetyl
Amantadine concentrations). An ongoing follow up will serve as part of our surveillance and strengthen the clinical
applicability of our data.
-
3. Compilation of the package to be filed with Health Canada has begun and a team has been assembled to
accelerate the submission.
Next Steps
News will be released as soon as the submission package is completed in the next couple of weeks.
About BioMark Diagnostics Inc.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help,
detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response
to treatment and potentially for serial monitoring for cancer survivors.
Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca .
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-307-0779
Email: info@biomarkdiagnostics.com
Copyright (c) 2018 TheNewswire - All rights reserved.